Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.
By LINDA A. JOHNSON and STEVE ROTHWELL As, San Jose Mercury News: Business
Sun, 11/23/2014 - 7:36am
Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and low interest rates are also fueling the mergers and acquisitions.